ID

42540

Descrizione

Study ID: 105874 Clinical Study ID: 105874 Study Title: Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00307021 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049 Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/NCT00307021. A Phase II randomized, double-blind bridging study of the safety and immunogenicity of GlaxoSmithKline Plasmodium falciparum malaria vaccine RTS,S/AS01E (0.5 mL dose) to RTS,S/AS02D (0.5 mL dose) administered IM according to a 0, 1, 2- month vaccination schedule in children aged 18 months to 4 years living in Gabon. Clinical Visits: This study has a total of 7 visits. Visit 1 = Screening, Visits 2-6 are during the double-blind phase (Month 0-3) and Visit 7 is during the single-blind phase (Month 4-14). Vaccine administration takes place during visits 2, 4, and 5 (Visit 2 = Dose 1; Visit 4 = Dose 2; Visit 5 = Dose 3). Field-worker Visits: During the double-blind phase, clinical visits are accompanied by daily field-worker visits subsequent to each vaccine administration visit. Additional field-worker visits also take place during months 4 to 13 of the single-blind phase. For all subjects enrolled, please complete the study conclusion form. The study conclusion should be documented subsequently to clinical visit 7 in separate forms for the double-blind and the single-blind phase respectively. The 'Status of Treatment Blind' item group only needs to be completed within the form for the double-blind phase. Note that informed consent has to be obtained prior to any study procedure.

collegamento

https://clinicaltrials.gov/ct2/show/NCT00307021

Keywords

versioni (1)
  1. 24/08/21 24/08/21 -
Titolare del copyright

GlaxoSmithKline

Caricato su

24 agosto 2021

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Safety & Immunogenicity of two GSK Biologicals' Candidate Malaria Vaccines in young children, NCT00307021

Inglese

Study Conclusion

1 moduli  
  1. StudyEvent: ODM
    1. Study Conclusion
Administrative Documentation
Descrizione

Administrative Documentation

Alias
UMLS CUI-1
C1320722
Date of visit
Descrizione

Date of visit

Tipo di dati

date

Alias
UMLS CUI [1]
C1320303
Subject number
Descrizione

Subject number

Tipo di dati

integer

Alias
UMLS CUI [1]
C2348585
Study phase
Descrizione

Please specify the study phase for which the form is filled in.

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C0205390
UMLS CUI [1,2]
C2603343
Occurrence of Serious Adverse Events
Descrizione

Occurrence of Serious Adverse Events

Alias
UMLS CUI-1
C1519255
Did the subject experience any Serious Adverse Event during the study period?
Descrizione

Serious adverse event during clinical trial period

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
If yes, specify total number of SAEs.
Descrizione

Serious adverse event during clinical trial period count specification

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
UMLS CUI [1,4]
C0750480
UMLS CUI [1,5]
C1521902
Status of Treatment Blind
Descrizione

Status of Treatment Blind

Alias
UMLS CUI-1
C0749659
UMLS CUI-2
C2347038
Was the treatment blind broken during the study?
Descrizione

Only to be completed for the double-blind phase version of the form. If yes, complete date and tick one reason in the following items.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
Date of breaking treatment blind
Descrizione

Subject unblinding event record date

Tipo di dati

date

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0011008
Reason for breaking treatment blind
Descrizione

Please tick one reason. If [9] other, please specify in the following item. Also complete Non-Serious Adverse Event section or a Serious Adverse Event report as appropriate.

Tipo di dati

text

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205225
If other, please specify
Descrizione

Subject unblinding event record other reason to specify

Tipo di dati

text

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C1521902
Elimination Criteria
Descrizione

Elimination Criteria

Alias
UMLS CUI-1
C0680251
Did any elimination criteria become applicable during the study?
Descrizione

Elimination criteria during clinical trial period

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
If yes, please specify.
Descrizione

Elimination criteria to specify

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1521902
Was the subject withdrawn from the study?
Descrizione

For the double-blind phase: Is the subject withdrawn from the double-blind phase? (A subject is withdrawn from the interim analysis if he/she did not come for the doublie blind phase - interim analysis timepoint visit.)

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0422727
If yes, indicate the major reason for withdrawal.
Descrizione

Please tick one box only. If serious adverse event [SAE], please complete and submit SAE report.

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205225
If death [DEA], please specify SAE number.
Descrizione

Death-related serious adverse event number to specify

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C1705232
UMLS CUI [1,2]
C1519255
UMLS CUI [1,3]
C0237753
UMLS CUI [1,4]
C1521902
If serious adverse event [SAE], please specify SAE number.
Descrizione

Serious adverse event number to specify

Tipo di dati

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0237753
UMLS CUI [1,3]
C1521902
If protocol violation [PTV], please specify.
Descrizione

Protocol violation to specify

Tipo di dati

text

Alias
UMLS CUI [1,1]
C1709750
UMLS CUI [1,2]
C1521902
If other [OTH], please specify.
Descrizione

Withdrawal other reason to specify

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0205394
UMLS CUI [1,4]
C1521902
If subject was withdrawn from the study, indicate who made the decision.
Descrizione

Withdrawal decision maker

Tipo di dati

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0679006
If subject was withdrawn from the study, indicate the date of the last contact.
Descrizione

Withdrawal date of last contact

Tipo di dati

date

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C0805839
If subject was withdrawn from the study, was the subject in good condition at date of last contact?
Descrizione

If no, please give details in Adverse Events section.

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C1142435
UMLS CUI [1,3]
C0805839
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
Descrizione

I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.

Alias
UMLS CUI-1
C2346576
Investigator's signature
Descrizione

Investigator signature

Tipo di dati

text

Alias
UMLS CUI [1]
C2346576
Printed investigator's name
Descrizione

Investigator name

Tipo di dati

text

Alias
UMLS CUI [1]
C2826892
Date
Descrizione

Investigator signature date

Tipo di dati

date

Alias
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Ritorna all'inizio della pagina

Similar models

Study Conclusion

1 moduli
  1. StudyEvent: ODM
    1. Study Conclusion
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Date of visit
Item
Date of visit
date
C1320303 (UMLS CUI [1])
Subject number
Item
Subject number
integer
C2348585 (UMLS CUI [1])
Item
Study phase
integer
C0205390 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
Study phase
Code List
Study phase
CL Item
double-blind phase (1)
(Comment:en)
CL Item
single-blind phase (2)
(Comment:en)
Item Group
Occurrence of Serious Adverse Events
C1519255 (UMLS CUI-1)
Serious adverse event during clinical trial period
Item
Did the subject experience any Serious Adverse Event during the study period?
boolean
C1519255 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Serious adverse event during clinical trial period count specification
Item
If yes, specify total number of SAEs.
integer
C1519255 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
C0750480 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
Item Group
Status of Treatment Blind
C0749659 (UMLS CUI-1)
C2347038 (UMLS CUI-2)
Subject unblinding event record during clinical trial period
Item
Was the treatment blind broken during the study?
boolean
C3897431 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Subject unblinding event record date
Item
Date of breaking treatment blind
date
C3897431 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Item
Reason for breaking treatment blind
text
C3897431 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
Subject unblinding event record reason and justification
Code List
Reason for breaking treatment blind
CL Item
Medical emergency requiring identification of investigational product for further treatments ([1])
CL Item
Other ([9])
Subject unblinding event record other reason to specify
Item
If other, please specify
text
C3897431 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Item Group
Elimination Criteria
C0680251 (UMLS CUI-1)
Elimination criteria during clinical trial period
Item
Did any elimination criteria become applicable during the study?
boolean
C0680251 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
Elimination criteria to specify
Item
If yes, please specify.
text
C0680251 (UMLS CUI [1,1])
C1521902 (UMLS CUI [1,2])
Patient withdrawn from trial
Item
Was the subject withdrawn from the study?
boolean
C0422727 (UMLS CUI [1])
Item
If yes, indicate the major reason for withdrawal.
text
C0422727 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
Withdrawal reason and justification primary
Code List
If yes, indicate the major reason for withdrawal.
CL Item
Death ([DEA])
CL Item
Serious adverse event ([SAE])
CL Item
Protocol violation ([PTV])
CL Item
Consent withdrawal, not due to an adverse event ([CWS])
CL Item
Migrated / moved from the study area ([MIG])
CL Item
Lost to follow-up ([LFU])
CL Item
Other ([OTH])
Death-related serious adverse event number to specify
Item
If death [DEA], please specify SAE number.
integer
C1705232 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Serious adverse event number to specify
Item
If serious adverse event [SAE], please specify SAE number.
integer
C1519255 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
Protocol violation to specify
Item
If protocol violation [PTV], please specify.
text
C1709750 (UMLS CUI [1,1])
C1521902 (UMLS CUI [1,2])
Withdrawal other reason to specify
Item
If other [OTH], please specify.
text
C0422727 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Item
If subject was withdrawn from the study, indicate who made the decision.
text
C0422727 (UMLS CUI [1,1])
C0679006 (UMLS CUI [1,2])
Trial Screen Failure | withdrawal before randomization | withdrawal before vaccination
Code List
If subject was withdrawn from the study, indicate who made the decision.
CL Item
Investigator ([I])
CL Item
Parents/Guardians ([P])
Withdrawal date of last contact
Item
If subject was withdrawn from the study, indicate the date of the last contact.
date
C0422727 (UMLS CUI [1,1])
C0805839 (UMLS CUI [1,2])
Withdrawal general physical condition date last contact
Item
If subject was withdrawn from the study, was the subject in good condition at date of last contact?
boolean
C0422727 (UMLS CUI [1,1])
C1142435 (UMLS CUI [1,2])
C0805839 (UMLS CUI [1,3])
Item Group
I confirm that I have reviewed the data in this Case Report Form for this subject. All information entered by myself or my colleagues is, to the best of my knowledge, complete and accurate, as of the date below.
C2346576 (UMLS CUI-1)
Investigator signature
Item
Investigator's signature
text
C2346576 (UMLS CUI [1])
Investigator name
Item
Printed investigator's name
text
C2826892 (UMLS CUI [1])
Investigator signature date
Item
Date
date
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial